General Information of Drug (ID: DME2PY5)

Drug Name
Midodrine
Synonyms
Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
Indication
Disease Entry ICD 11 Status REF
Orthostatic hypotension BA21 Approved [1]
Therapeutic Class
Vasoconstrictor Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 254.28
Logarithm of the Partition Coefficient (xlogp) -0.6
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Bioavailability
93% of drug becomes completely available to its intended biological destination(s) [2]
Clearance
The renal clearance of drug is 385 mL/min []
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 4 hours [3]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.98314 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.7% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.67 L/kg [3]
Chemical Identifiers
Formula
C12H18N2O4
IUPAC Name
2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
Canonical SMILES
COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O
InChI
InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
InChIKey
PTKSEFOSCHHMPD-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4195
ChEBI ID
CHEBI:6933
CAS Number
42794-76-3
DrugBank ID
DB00211
TTD ID
D02XJY
VARIDT ID
DR01164
INTEDE ID
DR1088
ACDINA ID
D00430
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor Alpha-1 (ADRA1) TTG28O6 NOUNIPROTAC Agonist [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME
DECB0K3 CP2D6_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Midodrine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylergonovine DMBEX4O Major Additive hypertensive effects by the combination of Midodrine and Methylergonovine. Abortion [JA00] [8]
Methylene blue DMJAPE7 Moderate Additive hypertensive effects by the combination of Midodrine and Methylene blue. Acquired methaemoglobinaemia [3A93] [9]
Ranolazine DM0C9IL Moderate Decreased metabolism of Midodrine caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [10]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Midodrine caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [11]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Midodrine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [12]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Midodrine and Droxidopa. Autonomic nervous system disorder [8D87] [13]
Linezolid DMGFPU2 Major Additive hypertensive effects by the combination of Midodrine and Linezolid. Bacterial infection [1A00-1C4Z] [14]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Midodrine and Levomilnacipran. Chronic pain [MG30] [15]
Selegiline DM6034S Moderate Additive hypertensive effects by the combination of Midodrine and Selegiline. Depression [6A70-6A7Z] [9]
Duloxetine DM9BI7M Moderate Increased risk of rapid heart rate by the combination of Midodrine and Duloxetine. Depression [6A70-6A7Z] [15]
Isocarboxazid DMAF1NB Moderate Additive hypertensive effects by the combination of Midodrine and Isocarboxazid. Depression [6A70-6A7Z] [9]
Milnacipran DMBFE74 Moderate Increased risk of rapid heart rate by the combination of Midodrine and Milnacipran. Depression [6A70-6A7Z] [15]
Tranylcypromine DMGB5RE Moderate Additive hypertensive effects by the combination of Midodrine and Tranylcypromine. Depression [6A70-6A7Z] [9]
Desvenlafaxine DMHD4PE Moderate Additive hypertensive effects by the combination of Midodrine and Desvenlafaxine. Depression [6A70-6A7Z] [15]
Phenelzine DMHIDUE Moderate Additive hypertensive effects by the combination of Midodrine and Phenelzine. Depression [6A70-6A7Z] [9]
Venlafaxine DMR6QH0 Moderate Increased risk of rapid heart rate by the combination of Midodrine and Venlafaxine. Depression [6A70-6A7Z] [15]
Mirabegron DMS1GYT Moderate Decreased metabolism of Midodrine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [16]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Midodrine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [17]
Ergotamine DMKR3C5 Major Additive hypertensive effects by the combination of Midodrine and Ergotamine. Headache [8A80-8A84] [8]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Midodrine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Givosiran DM5PFIJ Moderate Decreased metabolism of Midodrine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [19]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Midodrine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [20]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Midodrine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [21]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Midodrine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Midodrine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [23]
Methysergide DM1EF73 Major Additive hypertensive effects by the combination of Midodrine and Methysergide. Migraine [8A80] [8]
Dihydroergotamine DM5IKUF Major Additive hypertensive effects by the combination of Midodrine and Dihydroergotamine. Migraine [8A80] [8]
Panobinostat DM58WKG Moderate Decreased metabolism of Midodrine caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [24]
Ozanimod DMT6AM2 Moderate Additive hypertensive effects by the combination of Midodrine and Ozanimod. Multiple sclerosis [8A40] [9]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Midodrine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [21]
Nilotinib DM7HXWT Moderate Decreased metabolism of Midodrine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [25]
Promethazine DM6I5GR Moderate Increased plasma concentrations of Midodrine and Promethazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [26]
Rolapitant DM8XP26 Moderate Decreased metabolism of Midodrine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [27]
Sibutramine DMFJTDI Moderate Increased risk of rapid heart rate by the combination of Midodrine and Sibutramine. Obesity [5B80-5B81] [28]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Midodrine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [29]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Midodrine and Rasagiline. Parkinsonism [8A00] [9]
Ergonovine DM0VEC1 Major Additive hypertensive effects by the combination of Midodrine and Ergonovine. Postpartum haemorrhage [JA43] [8]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Midodrine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [30]
⏷ Show the Full List of 38 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Midodrine 10 mg tablet 10 mg Oral Tablet Oral
Midodrine 2.5 mg tablet 2.5 mg Oral Tablet Oral
Midodrine 5 mg tablet 5 mg Oral Tablet Oral
Midodrine Hydrochloride 10mg tablet 10mg Tablet Oral
Midodrine Hydrochloride 5mg tablet 5mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7240).
2 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.
6 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
7 Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
8 Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9. [PMID: 2881898]
9 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
10 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
11 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
12 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
13 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
14 Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK "Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr." J Clin Pharmacol 41 (2001): 563-72. [PMID: 11361053]
15 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
16 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
17 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
18 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
19 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
20 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
24 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
26 Platts SH, Shi SJ, Meck JV "Akathisia with combined use of midodrine and promethazine." JAMA 295 (2006): 2000-1. [PMID: 16670408]
27 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
28 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
29 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
30 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.